Hasil Pencarian - Olaf-Oliver Wolz

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant

    A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant oleh Olaf-Oliver Wolz, Sarah-Katharina Kays, Helga Junker, Sven D. Koch, Philipp Mann, Gianluca Quintini, Philipp von Eisenhart-Rothe, Lidia Oostvogels

    Diterbitkan 2022-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling

    Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling oleh Yamel Cardona Gloria, Yamel Cardona Gloria, Stephan H. Bernhart, Stephan H. Bernhart, Stephan H. Bernhart, Sven Fillinger, Olaf-Oliver Wolz, Olaf-Oliver Wolz, Sabine Dickhöfer, Sabine Dickhöfer, Jakob Admard, Stephan Ossowski, Sven Nahnsen, Reiner Siebert, Reiner Siebert, Alexander N. R. Weber, Alexander N. R. Weber, Alexander N. R. Weber

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity

    Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity oleh Olaf-Oliver Wolz, Dominik Vahrenhorst, Gianluca Quintini, Christina Lemberg, Sven D. Koch, Sarah-Katharina Kays, Lisa Walz, Neeraja Kulkarni, Michael Fehlings, Peter Wengenmayer, Jana Heß, Lidia Oostvogels, Sandra Lazzaro, Philipp von Eisenhart-Rothe, Philipp Mann

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

    HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy oleh Annika Nelde, Juliane Sarah Walz, Daniel Johannes Kowalewski, Heiko Schuster, Olaf-Oliver Wolz, Janet Kerstin Peper, Yamel Cardona Gloria, Anton W. Langerak, Alice F. Muggen, Rainer Claus, Irina Bonzheim, Falko Fend, Helmut Rainer Salih, Lothar Kanz, Hans-Georg Rammensee, Stefan Stevanović, Alexander N. R. Weber

    Diterbitkan 2017-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]

    Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] oleh Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, Morgan Hess-Holtz, Geert Leroux-Roels, Helga Junker, Sarah-Katharina Kays, Sven D. Koch, Sandra Lazzaro, Philipp Mann, Gianluca Quintini, Barkha Srivastava, Dominik Vahrenhorst, Philipp von Eisenhart-Rothe, Olaf-Oliver Wolz, Lidia Oostvogels

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study

    Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study oleh Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, Carlos R. Celis, Rubelio Cornejo, Rodrigo DeAntonio, Lucie Ecker, Diegi Garrido, Ana I. Gil, Marina Gonzales, Morgan Hess-Holtz, Geert Leroux-Roels, Helga Junker, Sarah-Katharina Kays, Sven D. Koch, Sandra Lazzaro, Philipp Mann, Gianluca Quintini, Barkha Srivastava, Dominik Vahrenhorst, Philipp von Eisenhart-Rothe, Olaf-Oliver Wolz, Lidia Oostvogels

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study

    Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study oleh Brandon J. Essink, Craig Shapiro, Marie Grace Dawn Isidro, Paul Bradley, Antoinette Pragalos, Mark Bloch, Joel Santiaguel, Melchor Victor Frias, Spiros Miyakis, Margarida Alves de Mesquita, Stefano Berrè, Charlotte Servais, Natasha Waugh, Claudia Hoffmann, Emna Baba, Oliver Schönborn-Kellenberger, Olaf-Oliver Wolz, Sven D. Koch, Tapiwa Ganyani, Philippe Boutet, Philipp Mann, Stefan O. Mueller, Roshan Ramanathan, Martin Robert Gaudinski, Nicolas Vanhoutte

    Diterbitkan 2024-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: